Literature DB >> 10421556

Status epilepticus: an overview of the clinical problem.

D H Lowenstein1.   

Abstract

Status epilepticus has been recognized since antiquity. The terms état de mal and "status epilepticus" are derived from the slang used by epilepsy patients housed in Salpêtrière and Bicêtre hospitals in Paris during the 1800s. The definition of status epilepticus has been evolving, and is still not precise. In 1903-04 it was described as a development of epilepsy in which seizures are so frequent that "coma and exhaustion are continuous between seizures." In 1964 the International League Against Epilepsy adopted the definition "a seizure [that] persists for a sufficient length of time or is repeated frequently enough to produce a fixed and enduring epileptic condition." 30 min has been the most common specified duration of seizures for the diagnosis of status epilepticus, although a duration of 10 or 20 min has been suggested as well. However, a new set of definitions for generalized, convulsive status epilepticus in adults has been proposed and includes an operational definition (specifying a seizure duration of a least 5 min) and a mechanistic definition. In the future, laboratory tests will provide the means for detecting and defining the critical factors that distinguish a single epileptic seizure from status epilepticus. Recent epidemiological studies suggest status epilepticus occurs in 100,000 to 150,000 people in the US each year, and is associated with substantial morbidity and mortality. Etiology, duration of the seizures, and the patient's age seem to be important determinants of the outcome in status epilepticus.

Entities:  

Mesh:

Year:  1999        PMID: 10421556     DOI: 10.1111/j.1528-1157.1999.tb00872.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  32 in total

Review 1.  Admission to neurological intensive care: who, when, and why?

Authors:  Robin S Howard; Dimitri M Kullmann; Nicholas P Hirsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 2.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

4.  Can status epilepticus sometimes just be a long seizure?

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2013-05       Impact factor: 7.500

5.  Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.

Authors:  Sudhir Sivakumaran; Jamie Maguire
Journal:  Epilepsia       Date:  2015-12-11       Impact factor: 5.864

6.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

7.  Emergency Neurological Life Support: Status Epilepticus.

Authors:  Jan Claassen; Joshua N Goldstein
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 8.  Emergency Neurological Life Support: Status Epilepticus.

Authors:  Jan Claassen; James J Riviello; Robert Silbergleit
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

9.  Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit.

Authors:  M Holtkamp; J Othman; K Buchheim; H Meierkord
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

10.  A single early-life seizure impairs short-term memory but does not alter spatial learning, recognition memory, or anxiety.

Authors:  Brandon J Cornejo; Michael H Mesches; Timothy A Benke
Journal:  Epilepsy Behav       Date:  2008-08-15       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.